Phospholipidosis in immune cells
Phospholipidosis (PLD) in immune cells, such as macrophages dendritic cells and lymphocytes, is triggered when compounds, particularly CADs, cause the accumulation of phospholipids in lysosomes, forming multilamellar bodies (lamellar body formation).
This lysosomal lipid buildup can interfere with key immune cell function, including:
How immune-cell phospholipidosis assays work
In a typical immune-cell PLD assay, immune cells are cultured in vitro and exposed to test compounds, including CADs. Fluorescent dyes (e.g., LipidTOX™) selectively stain phospholipid-rich lysosomes, allowing visualization of lysosomal multilamellar bodies.
Immune-cell PLD is a key mechanism in drug-induced immunotoxicity, making early detection critical in preclinical drug development.
How to choose an immune-cell phospholipidosis assay
Selecting the right assay depends on your research objectives and immune-cell model.
Essential factors include:
Additional factors such as assay sensitivity, throughput, and reproducibility should also be considered.
Key PLD assay considerations
Several factors influence the accuracy and robustness of immune-cell PLD assays, such as:
Our immune-cell phospholipidosis assay service
We provide a comprehensive PLD assay service for immune cells, delivering reliable preclinical safety and immunotoxicity data.
Our cell-based PLD assays assess how compounds affect cell safety in immune cells. To measure PLD, we employ fluorescent dyes like Nile Red and LipidTOX™ that specifically highlight lysosomes rich in phospholipids.
Direct access to high-quality immune cells
Through our sister company of BIOMEX, we maintain access to:
What we support you with
We partner with you to design and deliver bioassays tailored to your specific needs:
Contact us